- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.08. | Senti Biosciences Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.07. | Senti Biosciences to spin off gene therapy unit for CVR | 5 | Investing.com | ||
| SENTI BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 15.07. | Senti Biosciences gliedert Gentherapie-Sparte gegen Meilensteinzahlungen aus | 14 | Investing.com Deutsch | ||
| 15.07. | Senti Biosciences, Inc.: Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines ... | 536 | GlobeNewswire (Europe) | Senti Biosciences Holdings, Inc. to Advance Controllable Cell and Gene Therapies Leveraging the Regulator Dial PlatformSpin-off of Senti Biosciences, Inc., including SENTI-202, Aims to Unlock Value... ► Artikel lesen | |
| 15.07. | Senti Biosciences Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.05. | Senti Biosciences Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Senti Biosciences Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.05. | Senti Biosciences GAAP EPS of -$0.14, revenue of $0.01M | 1 | Seeking Alpha | ||
| 14.05. | Senti Bio plans pivotal trial for AML therapy after FDA meeting | 6 | Investing.com | ||
| 14.05. | Senti Biosciences Holdings, Inc. - 8-K, Current Report | 7 | SEC Filings | ||
| 14.05. | Senti Biosciences, Inc.: Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase | 446 | GlobeNewswire (Europe) | Secured strategic financing vehicle for up to $40 million Positive FDA feedback supports single-arm pivotal trial for potential registration of SENTI-202 in initial indication of Relapsed/Refractory... ► Artikel lesen | |
| 14.05. | Senti Biosciences, Inc.: Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 ... | 427 | GlobeNewswire (Europe) | Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep... ► Artikel lesen | |
| 08.05. | Senti Biosciences, Inc. - 15-12G, Securities registration termination | - | SEC Filings | ||
| 01.05. | Senti Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.04. | Senti Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 13.04. | Senti Biosciences, Inc.: Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026 | 5 | GlobeNewswire (USA) | ||
| 01.04. | Senti Biosciences publishes CAR circuit research in Cell Systems | 1 | Investing.com | ||
| 01.04. | Senti Biosciences, Inc.: Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies | 1 | GlobeNewswire (USA) | ||
| 27.03. | Senti Biosciences stock rating held at Buy by H.C. Wainwright | 2 | Investing.com | ||
| 27.03. | Senti Biosciences Non-GAAP EPS of -$0.53 misses by $0.06 | 13 | Seeking Alpha |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 3,348 | -1,06 % | Rheinmetall-Aktie verkaufen? Evotec mit KI-Fantasie? Lahontan Gold hebt Ressourcenschätzung um 22 %! | Soll man die Rheinmetall-Aktie verkaufen? Dazu rät jedenfalls mwb Research. Die Analysten sehen Rheinmetall operativ weiterhin als klaren Gewinner des europäischen Rüstungsbooms. Doch die Erwartungen... ► Artikel lesen | |
| MEDIGENE | 0,006 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| QIAGEN | 37,590 | -0,42 % | QIAGEN ernennt Jonathan M. Pratt zum Vorstandschef | Bad Marienberg (www.anleihencheck.de) - QIAGEN N.V. ((ISIN NL0015001WM6/ WKN A41HBE; NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Ernennung von Jonathan M. Pratt zum Vorstandsvorsitzenden... ► Artikel lesen | |
| VALNEVA | 2,798 | +0,76 % | Katalysator voraus: Valneva (ISIN: FR0004056851) setzt auf Q3-Shigella-Daten | ||
| STRYKER | 285,30 | -0,07 % | Do Options Traders Know Something About Stryker Stock We Don't? | ||
| ILLUMINA | 186,64 | +0,27 % | $100 Invested In Illumina 20 Years Ago Would Be Worth This Much Today | ||
| CRISPR THERAPEUTICS | 49,360 | -0,85 % | CRISPR Therapeutics legt positive Einjahresdaten für Gentherapie CTX310 vor | ||
| REGENERON PHARMACEUTICALS | 682,40 | -0,41 % | Veeva Systems: Veeva Vault CRM Selected by Regeneron | Leading biopharma company selects agentic CRM for life sciences to generate Commercial EvidencePLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced... ► Artikel lesen | |
| BRAIN BIOTECH | 2,670 | +0,38 % | EQS-News: BRAIN Biotech AG: BRAIN Biotech berichtet 9M-Zahlen und strebt unverändert ein ausgeglichenes bereinigtes Konzern-EBITDA an | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): 9-Monatszahlen/Quartals-/Zwischenmitteilung
BRAIN Biotech berichtet 9M-Zahlen und strebt unverändert ein ausgeglichenes bereinigtes... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones | PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program Proposed... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,850 | +0,36 % | Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough? | ||
| INTELLIA THERAPEUTICS | 11,220 | +0,90 % | Cathie Wood's ARK buys Intellia stock, sells Roblox | ||
| BAVARIAN NORDIC | 28,400 | -0,21 % | Bavarian Nordic A/S: Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such | ||
| TEMPUS AI | 55,25 | -0,04 % | Tempus AI (TEM) Jumped on Moderna's Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated? | ||
| BIO-GATE | 2,700 | -0,37 % | Bio-Gate nimmt mit Kapitalerhöhungen 1,16 Millionen Euro ein | Bio-Gate hat die Kapitalerhöhung aus genehmigtem Kapital sowie die von der Hauptversammlung beschlossene Bezugsrechtsemission abgeschlossen. Insgesamt wurden 415.000 neue Aktien zu jeweils 2,80 Euro... ► Artikel lesen |
SENTI BIOSCIENCES HOLDINGS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,007 (-1,86 %) liegt der Kurs bei 0,370 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SENTI BIOSCIENCES HOLDINGS INC finden Sie auf Wallstreet Online.